SAN
JOSE, Calif., Feb. 25,
2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa"
or the "Company") (NASDAQ: ANIX), a biotechnology company focused
on the treatment and prevention of cancer, today announced that its
breast cancer vaccine was featured on Fox News' "America Reports."
The segment highlighted the potential of Anixa's vaccine to
revolutionize breast cancer prevention by targeting the disease at
its earliest stages.
Anixa's breast cancer vaccine is designed to train the immune
system to recognize and eliminate cancerous cells before they can
develop into invasive tumors. The vaccine targets a lactation
protein, α-lactalbumin, which is only expressed in the breast when
a woman is lactating but not at other times in her life or in other
tissues. However, when a woman develops breast cancer, including
TNBC or other types of breast cancer, many of the malignant cells
will express α-lactalbumin. Activating the immune system, through
vaccination, to direct cytotoxic T cells to the tumor cell
expressing this protein may provide preemptive immune protection
against emerging breast tumors that express α-lactalbumin.
"We are pleased to have our breast cancer vaccine featured on
Fox News' 'America Reports,' as this national exposure brings
greater awareness to the importance of preventative cancer
immunotherapy," said Dr. Amit Kumar,
Chairman and CEO of Anixa Biosciences. "We believe we have made
significant strides, and we are optimistic about the impact this
vaccine could have in reducing the incidence of triple-negative
breast cancer as well as other breast cancers."
The Phase I clinical trial, conducted in collaboration with
Cleveland Clinic and funded by a grant from the U.S. Department of
Defense, continues to show promising progress. As additional
patients are enrolled across all three cohorts, Anixa is encouraged
by the positive data trends emerging. The vaccine has demonstrated
a strong safety profile, being well tolerated by participants, with
protocol-defined immune responses observed in over 70% of patients.
Looking ahead, a Phase 2 study in the neoadjuvant setting is
planned to begin in 2025, representing a critical milestone in the
vaccine's continued development.
To watch the Fox News "America Reports" feature, please visit
Anixa's YouTube channel:
https://www.youtube.com/watch?v=PIvp5oiK-Ac.
About Anixa Biosciences, Inc.
Anixa is a
clinical-stage biotechnology company focused on the treatment and
prevention of cancer. Anixa's therapeutic portfolio consists of an
ovarian cancer immunotherapy program being developed in
collaboration with Moffitt Cancer Center, which uses a novel type
of CAR-T, known as chimeric endocrine receptor-T cell (CER-T)
technology. The Company's vaccine portfolio includes vaccines being
developed in collaboration with Cleveland Clinic to treat and
prevent breast cancer and ovarian cancer, as well as additional
cancer vaccines to address many intractable cancers, including high
incidence malignancies in lung, colon, and prostate. These vaccine
technologies focus on immunizing against "retired" proteins that
have been found to be expressed in certain forms of cancer. Anixa's
business model of partnering with world-renowned research
institutions on all stages of development allows the Company to
continually examine emerging technologies in complementary fields
for further development and commercialization. To learn more, visit
www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook
and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are not statements of historical facts, but rather
reflect Anixa's current expectations concerning future events and
results. We generally use the words "believes," "expects,"
"intends," "plans," "anticipates," "likely," "will" and similar
expressions to identify forward-looking statements. Such
forward-looking statements, including those concerning our
expectations, involve risks, uncertainties and other factors, some
of which are beyond our control, which may cause our actual
results, performance or achievements, or industry results, to be
materially different from any future results, performance, or
achievements expressed or implied by such forward-looking
statements. These risks, uncertainties and factors include, but are
not limited to, those factors set forth in "Item 1A - Risk Factors"
and other sections of our most recent Annual Report on Form 10-K as
well as in our Quarterly Reports on Form 10-Q and Current Reports
on Form 8-K. We undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.
You are cautioned not to unduly rely on such forward-looking
statements when evaluating the information presented in this press
release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download
multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-breast-cancer-vaccine-was-featured-on-fox-news-america-reports-302384318.html
SOURCE Anixa Biosciences, Inc.
